1. Outcome of gestational trophoblastic neoplasia: experience from a tertiary cancer centre in India.
- Author
-
Gulia S, Bajpai J, Gupta S, Maheshwari A, Deodhar K, Kerkar RA, Seth V, Rekhi B, and Menon S
- Subjects
- Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cyclophosphamide administration & dosage, Cyclophosphamide adverse effects, Dactinomycin administration & dosage, Dactinomycin adverse effects, Etoposide administration & dosage, Etoposide adverse effects, Female, Humans, India, Methotrexate administration & dosage, Methotrexate adverse effects, Methotrexate therapeutic use, Middle Aged, Pregnancy, Salvage Therapy, Survival Analysis, Tertiary Care Centers, Treatment Outcome, Vincristine administration & dosage, Vincristine adverse effects, Young Adult, Choriocarcinoma drug therapy, Gestational Trophoblastic Disease drug therapy
- Abstract
Aims: Gestational trophoblastic neoplasms (GTN) comprise a spectrum of interrelated conditions originating from the placenta. With sensitive assays for human chorionic gonadotropin (β-hCG) and current approaches to chemotherapy, most women with GTN can be cured with preservation of reproductive potential. The purpose of this analysis was to address the outcome of GTN from a developing country, as data are largely sparse from this region., Materials and Methods: We undertook a retrospective review of GTN cases treated at our centre from 2001 to 2008. Patients of GTN were assigned to low-risk (score ≤ 6) or high-risk (score ≥ 7) categories as per the modified World Health Organization scoring system. The low-risk group was treated with single-agent methotrexate (MTX) and the high-risk group received the EMA/CO regimen. Salvage therapies were EMA/EP or BEP. Treatment was continued until serum β-hCG values were normal for three consecutive chemotherapy cycles, after which the patients were kept on follow-up., Results: In total, 70 GTN patients were treated at our institution during this period; 48 (68%) were low-risk and 22 (32%) were in the high-risk category. The median β-hCG level was 50 000 IU/l. The lung was the most common site of metastasis, seen in 15 (21%) patients. Among 48 low-risk patients, 37 (77%) received chemotherapy, of whom 25 (68%) were treated with MTX and 24 (96%) achieved a complete response. Twelve low-risk patients (32%) received EMA/CO therapy; 10 (83%) achieved a complete response. The 22 high-risk patients received EMA/CO and of these 16 (73%) achieved a complete response, two (9%) progressed, two (9%) died of progressive disease and two (9%) were lost to follow-up. Grade 3/4 toxicities with MTX included mucositis in two (8%) and neutropenia in five (21%) patients. At a median follow-up of 16.6 months, overall survival in the low- and high-risk groups was 100 and 88.8%, respectively., Conclusion: Risk-stratified treatment of GTN was associated with acceptable toxicity and resulted in outcome that was comparable with international standards., (Copyright © 2013 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF